2,5-Diazabicyclo[4.2.0]octane GLP-1 Modulators for Oral Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular disease and metabolic conditions, such as type 2 diabetes, often require injectable GLP-1 peptide hormones with limited bioavailability and patient compliance issues due to their administration route and short half-life, necessitating a more effective and easily administered therapeutic option.
Innovation Solution
Development of novel GLP-1 receptor modulators, specifically compounds of Formula (I), which are designed to have improved safety, selectivity, and metabolic stability, potentially offering higher oral bioavailability and reduced side effects, for use in pharmaceutical compositions to treat cardiovascular disease and metabolic conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If injectable GLP-1 peptide hormones are used, then therapeutic efficacy is improved, but patient compliance and ease of administration deteriorate
Solution Approach 1:
The patent applies parameter changes by transitioning from peptide-based GLP-1 agonists to small molecule compounds, fundamentally changing the chemical parameters (molecular size, structure, properties) to enable oral administration while maintaining therapeutic efficacy. This allows the drug to be taken orally rather than via injection, significantly improving patient compliance.
2Reliability
If GLP-1 peptide hormones are used, then GLP-1 receptor activation is achieved, but half-life and metabolic stability deteriorate
Solution Approach 1:
The patent changes the chemical parameters from peptide structure to small molecule structure, which fundamentally alters metabolic stability and half-life characteristics. Small molecules generally exhibit improved metabolic stability and longer half-life compared to peptides, resolving the contradiction between maintaining receptor activation and improving duration of action.
3Ease of operation
If oral GLP-1 peptides are used, then ease of administration is improved, but bioavailability deteriorates
Solution Approach 1:
The patent changes the molecular parameters from large peptide molecules to small molecules, which fundamentally improves oral bioavailability. Small molecules can better penetrate biological membranes and resist degradation in the gastrointestinal tract, enabling effective oral delivery while maintaining ease of administration.
Data Source
AI summary
There are disclosed certain 2,5-diazabicyclo[4.2.0]octanes of formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are GLP-1 receptor modulators and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disease and metabolic conditions, for example Type 2 diabetes.